BELANTAMAB MAFODOTIN
Blenrep (belantamab mafodotin) is an antibody drug conjugate pharmaceutical. Belantamab mafodotin was first approved as Blenrep on 2020-08-05. It is used to treat multiple myeloma in the USA. It has been approved in Europe to treat multiple myeloma.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| blenrep | Biologic Licensing Application | 2022-02-28 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| multiple myeloma | — | D009101 | C90.0 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
belantamab mafodotin, Blenrep, GlaxoSmithKline Intellectual Property Development Ltd. England | |||
| 2027-08-05 | Orphan excl. | ||
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J9037 | Injection, belantamab mafodotin-blmf, 0.5 mg |
Clinical
Clinical Trials
57 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple myeloma | D009101 | — | C90.0 | 26 | 26 | 5 | — | 5 | 45 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Corneal diseases | D003316 | — | H18.9 | 3 | 3 | — | — | 1 | 4 |
| Neoplasms | D009369 | — | C80 | 3 | 3 | — | — | — | 3 |
| Hematologic diseases | D006402 | EFO_0005803 | D75.9 | 3 | 3 | — | — | — | 3 |
| Blood protein disorders | D001796 | — | — | 3 | 3 | — | — | — | 3 |
| Plasma cell neoplasms | D054219 | — | — | 3 | 3 | — | — | — | 3 |
| Paraproteinemias | D010265 | — | D47.2 | 3 | 3 | — | — | — | 3 |
| Immunoglobulin light-chain amyloidosis | D000075363 | — | — | 1 | 2 | — | — | — | 2 |
| Plasmablastic lymphoma | D000069293 | — | C83.3 | — | 1 | — | — | — | 1 |
| Amyloidosis | D000686 | EFO_1001875 | E85 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sepsis | D018805 | HP_0100806 | A41.9 | — | — | — | — | 1 | 1 |
| Agranulocytosis | D000380 | HP_0012234 | D70 | — | — | — | — | 1 | 1 |
| Opportunistic infections | D009894 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | BELANTAMAB MAFODOTIN |
| INN | belantamab mafodotin |
| Description | Belantamab mafodotin, sold under the brand name Blenrep, is a medication for the treatment of relapsed and refractory multiple myeloma.
|
| Classification | Antibody |
| Drug class | synthetic analogs of the dolastatin series; monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 2050232-20-5 |
| RxCUI | 2387844 |
| ChEMBL ID | CHEMBL4298209 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB15719 |
| UNII ID | DB1041CXDG (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 943 documents
View more details
Safety
Black-box Warning
Black-box warning for: Blenrep
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
720 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use